n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide and Cancer of Ovary

n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide has been researched along with Cancer of Ovary in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Ge, D; Meng, G; Zheng, W	1

Other Studies

1 other study(ies) available for n-(3-cyano-4-methyl-1h-indol-7-yl)-3-cyanobenzene-sulfonamide and Cancer of Ovary

Article	Year
Reversing microtubule-directed chemotherapeutic drug resistance by co-delivering α2β1 inhibitor and paclitaxel with nanoparticles in ovarian cancer. Cell biology international, 2020, Volume: 44, Issue:2 Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Indoles; Integrin alpha2beta1; Mice; Mice, Nude; Microtubules; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2020

Article

Year

Reversing microtubule-directed chemotherapeutic drug resistance by co-delivering α2β1 inhibitor and paclitaxel with nanoparticles in ovarian cancer.

Cell biology international, 2020, Volume: 44, Issue:2

Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Indoles; Integrin alpha2beta1; Mice; Mice, Nude; Microtubules; Nanoparticles; Ovarian Neoplasms; Paclitaxel; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2020